JNJ logo

Johnson & Johnson Stock Price

Symbol: NYSE:JNJMarket Cap: US$403.0bCategory: Pharmaceuticals & Biotech

JNJ Share Price Performance

JNJ Community Fair Values

Recent JNJ News & Updates

No updates

Johnson & Johnson Key Details

US$90.6b

Revenue

US$28.6b

Cost of Revenue

US$62.0b

Gross Profit

US$39.3b

Other Expenses

US$22.7b

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
Oct 14, 2025
Earnings per share (EPS)
9.41
Gross Margin
68.41%
Net Profit Margin
25.00%
Debt/Equity Ratio
64.7%

Johnson & Johnson Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About JNJ

Founded
1886
Employees
138100
CEO
Joaquin Duato
WebsiteView website
www.jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 10.7%
  • 1 Year: 17.5%
  • Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. As for the longer term, the market has actually risen by 18% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading